Anti-Complement C5 Reference Antibody (crovalimab)
Recombinant Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| FC, Kinetics, Animal Model |
---|---|
Primary Accession | P01031 |
Reactivity | Human |
Clonality | Monoclonal |
Isotype | IgG1 |
Calculated MW | 145 KDa |
Target/Specificity | Complement C5 |
---|---|
Endotoxin | < 0.001EU/ µg,determined by LAL method. |
Conjugation | Unconjugated |
Expression system | CHO Cell |
Format | Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column. |
Name | C5 {ECO:0000303|PubMed:1984448, ECO:0000312|HGNC:HGNC:1331} |
---|---|
Function | Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:6554279). Activated downstream of classical, alternative, lectin and GZMK complement pathways (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:6554279). |
Cellular Location | Secreted. [C5a anaphylatoxin]: Secreted |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.